ReviewWorld journal of urology2022
Active surveillance for prostate cancer: selection criteria, guidelines, and outcomes.
Review in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- A Pilot Study ofThe Prostate · 2026Article
- Analytical Validation of MyProstateScore 2.0-Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay.Diagnostics (Basel, Switzerland) · 2026Article
- Real-world monitoring strategies and predictors guiding the transition from active surveillance to treatment in ISUP 1 prostate cancer.Journal of cancer research and clinical oncology · 2026Article
- Clinical and MRI features for predicting maximum cancer involvement of >50% in a single biopsy core among patients diagnosed with prostate cancer at initial systematic biopsy: a machine learning study.American journal of cancer research · 2026Article
- Article
- MRI-based Habitat Imaging for Noninvasive Prediction of High-Grade Prostate Cancer.Radiology. Imaging cancer · 2025Article
- Accuracy, intra-, and inter-radiologist variability of PI-RADS v2.1 scoring for clinically significant prostate cancer detection.Quantitative imaging in medicine and surgery · 2025Article
- Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.Prostate cancer and prostatic diseases · 2025Observational
- MRI characteristics predict risk of pathological upgrade in patients with ISUP grade group 1 prostate cancer.European radiology · 2025Article
- Patient Reported Outcomes and Treatment-Associated Complications as a Consideration in Selecting Localized Prostate Cancer Management.Research and reports in urology · 2025Review
- Do 5-Alpha Reductase Inhibitors Influence the Features of Suspicious Lesions on Magnetic Resonance Imaging and Targeted Biopsy Results for Prostate Cancer Diagnosis?Diagnostics (Basel, Switzerland) · 2024Article
- Redefining prostate cancer risk stratification: a pioneering strategy to estimate outcome based on Ki67 immunoscoring.Biomarker research · 2024Article
- Proficiency score as a predictor of early trifecta achievement during the learning curve of robot-assisted radical prostatectomy for high-risk prostate cancer: Results of a multicentric series.Current urology · 2024Article
- Previous inguinal hernia surgery does not limit the likelihood of choosing prostatectomy as primary prostate cancer therapy.Scientific reports · 2024Article
- Applications of Urinary Extracellular Vesicles in the Diagnosis and Active Surveillance of Prostate Cancer.Cancers · 2024Review
- Exploring the relation of active surveillance schedules and prostate cancer mortality.Cancer medicine · 2024Article
- Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk.NPJ precision oncology · 2024Article
- A Systematic Review on Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) Evaluating Localized Low- to Intermediate-Risk Prostate Cancer: A Tool to Improve Risk Stratification for Active Surveillance?Life (Basel, Switzerland) · 2024Review
- Outcomes and predictors of clinically significant prostate cancer detection by transperineal computer fusion biopsy during active surveillance.Central European journal of urology · 2024Article
- The evolving landscape: magnetic resonance imaging in active surveillance for prostate cancer management.Frontiers in urology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionActive surveillance (AS) has been widely adopted for the management of men with low-risk prostate cancer. However, there is still a lack of consensus surrounding the optimal approach for monitoring men in AS protocols. While conservative management aims to reduce the burden of invasive testing without compromising oncological safety, inadequate assessment can result in misclassification and unintended over- or undertreatment, leading to increased patient morbidity, cost, and undue risk. No universally accepted AS protocol exists, although numerous strategies have been developed in an attempt to optimize the management of clinically localized disease. Variability in selection criteria, reclassification, triggers for definitive treatment, and follow-up exists between guidelines and institutions for AS. In this review, we summarize the landscape of AS by providing an overview of the existing AS protocols, guidelines, and their published outcomes.
methodsA comprehensive electronic search was performed to identify representative studies and guidelines pertaining to AS selection criteria and outcomes.
conclusionWhile AS is a safe and increasingly utilized treatment modality for lower-risk forms of PCa, ongoing research is needed to optimize patient selection as well as surveillance protocols along with improved implementation across practices. Further, assessment of companion risk assessment tools, such as mpMRI and tissue-based biomarkers, is also needed and will require rigorous prospective study.
Indexed as
Identifiers
33655428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.